Latest Respiratory Disease News

4DMedical has renewed its three-year contract with the University of Michigan Medical Center, reinforcing its foothold in US respiratory imaging. Alongside, a pivotal clinical study validates its technology’s ability to detect early lung disease, while a substantial Australian grant boosts its AI research.

Adherium Limited has successfully completed a $4.49 million entitlement offer, combining institutional and retail components, to fund expansion of its Hailie® digital respiratory monitoring platform.

Dimerix has received a US$30 million upfront payment from Amicus Therapeutics for exclusive US rights to DMX-200, a promising kidney disease therapy. The deal positions Dimerix for up to US$560 million in further milestones plus royalties, underpinning its global licensing strategy.

Dimerix Limited has announced a US licensing transaction for its Phase 3 asset DMX-200 targeting FSGS, alongside progress updates on its clinical trial. The move underscores the company’s push to address a rare kidney disease with no approved therapies.

4DMedical has signed a landmark commercial agreement with Qscan Radiology Clinics, marking its first Australian contract to integrate both Pulmonary Function and Pulmonary Structure imaging products.

Cyclopharm has inked a pivotal three-year agreement with HCA Healthcare, enabling deployment of its Technegas® lung imaging technology across up to 169 US nuclear medicine departments. This deal marks a major step in expanding Technegas®’ footprint in the American healthcare market.